EN DE
Watch Orthopediatrics Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Orthopediatrics Corp (KIDS) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Orthopediatrics Corp stock $27.02, price $31.50, that is 14.2% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US68752L1008

OC Orthopediatrics Corp logo Thin data Nov 17, 2026

Orthopediatrics Corp

KIDS · US

Expensive (fair value 14% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Generates free cash flow over the last twelve months 
Revenue last quarter +19% vs. a year ago. 
Quality 47/100 
Expensive Growth (revenue 5y +27.2 %/yr in USD) 
Insiders sold $15.6M (6M) 
Fair value $27.02 · Overvalued 
Loss-making · -12.8% net margin (TTM) · excl. goodwill write-downs -10.9% 
Trails peers (1/10) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Orthopediatrics Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$72.93 $14.64 Fair Value $27.02 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $14.64 – $72.93 · fair‑value band $20.26 – $33.77 · the $31.50 price screens above the $27.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Orthopediatrics in your weekly email

Every Wednesday you see whether Orthopediatrics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.

Show moreShow less

The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products.

Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers.

OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Stock analysis

Orthopediatrics Corp (KIDS) currently trades at $31.50, while our estimate is $27.02, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $20.26 (bear) to $33.77 (bull), the price of $31.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Orthopediatrics Corp reported revenue of $236M in FY2025 versus $98.0M in FY2021, a compound +24.6%/yr. Reported net income was −$39.6M in FY2025.

Key figures

Market cap $752M Small · P/S ratio 3.21 · EPS (TTM) $−1.42 · Net margin −12.8% · Return on equity −9.8% · Return on assets (EBIT) −6.0% (5-year average) · Revenue (TTM) $253M · Revenue growth (YoY) +18.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 115% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −14%, KIDS screens cheaper than that median.

Fair Value

Bear $20.26 Fair Value $27.02 Bull $33.77
Price $31.50 · Downside -14.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 87
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 94
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $15.6M and none bought.

  • SaleJennifer N. Pritzker10% owner4× since Aug 24, 2026: 700,000 shares, avg. $22.26$15.6MSep 10, 2026
  • SaleSquadron Capital Holdings LLC10% owner3× since Aug 24, 2026: 677,500 shares, avg. $22.22$15.1MSep 10, 2026
  • SaleDavid R PelizzonDirector, 10% owner4× since Aug 24, 2026: 700,000 shares, avg. $22.26$15.6MSep 10, 2026
  • SaleSquadron Capital LLC10% owner22,500 shares at $23.35$525,375Sep 2, 2026
  • SaleDaniel J GerritzenGeneral Counsel and Secretary8,614 shares at $17.25$148,592Mar 16, 2026
  • SaleGregory A OdlePresident of Scoliosis8,433 shares at $17.25$145,469Mar 16, 2026
  • SaleDavid R BaileyPresident and CEO, Director19,535 shares at $17.25$336,979Mar 16, 2026
  • SaleFred HiteCOO and CFO, Director12,993 shares at $17.25$224,129Mar 16, 2026
  • SaleJoseph W HauserPres. Trauma & Def. Correction8,596 shares at $17.25$148,281Mar 16, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.2%
Start year 2020 (pandemic). Over 10 years: +22.5% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.6% (2020) → −12.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

KIDS screens overvalued: fair value 14% below the price. Compare with Abbott Laboratories, →

Compare Orthopediatrics Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −14.2% · Below median
Profitability
Return on assets −7.8% · Below median
Net margin (12 months) −12.8% · Below median
Operating margin (12 months) −12.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 18.6% · Above median
Balance sheet
Debt / equity 0.29× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.17× · Pricier than median
P/S (12 months) 2.98× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)14 · sector 17
FUTURE (revenue growth)93 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs KIDS
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs KIDS
Stryker Corporation SYK $310.72 $340.60 +10% vs KIDS
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs KIDS
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs KIDS
Siemens Healthineers AG SHL €44.00 €34.51 −22% vs KIDS
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs KIDS
Medtronic plc MDT $102.88 $74.89 −27% vs KIDS
Abbott Laboratories, ABT $107.45 $75.28 −30% vs KIDS
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs KIDS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Orthopediatrics Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Orthopediatrics Corp Fair Value". https://www.fairvalue-calculator.com/stock/KIDS

Frequently asked questions

Is Orthopediatrics Corp (KIDS) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $27.02 versus a price of $31.50, about 14% lower (overvalued).
What is the fair value of KIDS?
Our estimate for Orthopediatrics Corp is $27.02 (as of Nov 17, 2026), built from audited fundamentals. The current price: $31.50.
What is the quality score of KIDS?
Orthopediatrics Corp has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orthopediatrics Corp (KIDS)?
Our calculated price target is the estimate of $27.02 (as of Nov 17, 2026). Cautious scenario $20.26, optimistic scenario $33.77. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Orthopediatrics Corp stock forecast for 2026?
Our estimate puts fair value at $27.02, about 14% lower versus a price of $31.50 (overvalued). Cautious scenario $20.26, optimistic scenario $33.77. The calculation is refreshed regularly with new filings.
What is the revenue of Orthopediatrics Corp (KIDS)?
Orthopediatrics Corp reported trailing-twelve-month revenue of about $253M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Orthopediatrics Corp (KIDS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orthopediatrics Corp it is $27.02 per share (as of Nov 17, 2026), against a price of $31.50.
Is Orthopediatrics Corp stock overvalued or undervalued in 2026?
As of Nov 17, 2026, KIDS trades above its calculated fair value: price $31.50, fair value $27.02, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KIDS?
No. The price is what the market pays today ($31.50); the fair value is what the company's own numbers justify ($27.02). For Orthopediatrics Corp the two are $4.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Orthopediatrics Corp worth?
The market values Orthopediatrics Corp at about $752M (market capitalisation, as of Nov 17, 2026). Per share that is $31.50; our models calculate a fair value of $27.02 per share.
What do the bullish and bearish scenarios say about KIDS?
Our models span a range for Orthopediatrics Corp: cautious scenario $20.26, base $27.02, optimistic $33.77 per share (as of Nov 17, 2026, price $31.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Orthopediatrics Corp (KIDS)?
Balance-sheet figures for Orthopediatrics Corp (as of Nov 17, 2026): return on equity −9.8%, debt of 0.29 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is KIDS from its 52-week high?
Orthopediatrics Corp trades at $31.50, about 7% below its 52-week high of $33.99 and 115% above the low of $14.64 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $27.02 is for.
Which stocks are comparable to Orthopediatrics Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orthopediatrics Corp stock attractive at the current price?
The data as of Nov 17, 2026: price $31.50, calculated fair value $27.02 (−14%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Orthopediatrics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orthopediatrics Corp (KIDS)?
The closing price on Nov 16, 2026 was $31.50. Our estimate is $27.02, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orthopediatrics Corp right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Orthopediatrics Corp

How large is the market capitalisation of Orthopediatrics Corp (KIDS)?
The market capitalisation of Orthopediatrics Corp is $752M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orthopediatrics Corp (KIDS)?
The price-to-sales ratio of Orthopediatrics Corp is 3.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Orthopediatrics Corp (KIDS)?
Earnings per share at Orthopediatrics Corp are $−1.42. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Orthopediatrics Corp (KIDS)?
The net margin of Orthopediatrics Corp is −12.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Orthopediatrics Corp (KIDS)?
The return on equity (ROE) of Orthopediatrics Corp is −9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orthopediatrics Corp (KIDS)?
On an EBIT basis the return on assets of Orthopediatrics Corp is −6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Orthopediatrics Corp (KIDS)?
Revenue at Orthopediatrics Corp is growing 18.6% versus a year earlier (3y avg +24.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Orthopediatrics Corp (KIDS) generate?
The free cash flow of Orthopediatrics Corp is −$16.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Orthopediatrics Corp (KIDS) carry?
The net debt of Orthopediatrics Corp is $80.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Orthopediatrics Corp in the live analysis

One click puts Orthopediatrics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.